Featured
Search Clinical Trials
Completed
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta (External Link)
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in …
Baylor Role:
Lead Sponsor
Completed
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma (External Link)
Subjects with MPM will undergo surgical mediastinal lymph node biopsy (cervical mediastinoscopy) and simultaneous surgical biopsy of the pleural tumor by thoracoscopy, at which time tumor tissue (at least 2 …
Baylor Role:
Lead Sponsor
Completed
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (External Link)
The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells …
Baylor Role:
Lead Sponsor
Completed
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders (External Link)
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take …
Baylor Role:
Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (External Link)
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role:
Lead Sponsor
Completed
39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity (External Link)
This study will enroll preterm infants who were scheduled to receive treatment for ROP by laser or Bevacizumab. We will observe the patients in the hospital for the cure of …
Baylor Role:
Lead Sponsor
Completed
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma (External Link)
With the exception of patients with diffuse intrinsic pontine glioma (DIPG), all patients should have the maximal surgical resection that can be safely performed prior to study entry. Submission of …
Baylor Role:
Lead Sponsor
Completed
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody (External Link)
Clostridium difficile is the leading cause of nosocomial diarrheal disease associated with antibiotic therapy. This is a debilitating condition with substantial morbidity and mortality that may be around 2-3%. Current …
Baylor Role:
Collaborator
Completed
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (External Link)
Three different doses of CTL will be evaluated: dose level I: 2 x 10e7/m2; dose level II: 5 x 10e7/m2; dose level III: 1 x 10e8/m2 Day 1 YTH 24/54 …
Baylor Role:
Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation (External Link)
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role:
Lead Sponsor